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Abstract
Background: Inhibitor of differentiation 4 (Id4), a member of the Id gene family is also a dominant
negative regulator of basic helix loop helix (bHLH) transcription factors. Some of the functions of
Id4 appear to be unique as compared to its other family members Id1, Id2 and Id3. Loss of Id4 gene
expression in many cancers in association with promoter hypermethylation has led to the proposal
that Id4 may act as a tumor suppressor. In this study we provide functional evidence that Id4 indeed
acts as a tumor suppressor and is part of a cancer associated epigenetic re-programming.
Methods: Data mining was used to demonstrate Id4 expression in prostate cancer. Methylation
specific polymerase chain reaction (MSP) analysis was performed to understand molecular
mechanisms associated with Id4 expression in prostate cancer cell lines. The effect of ectopic Id4
expression in DU145 cells was determined by cell cycle analysis (3H thymidine incorporation and
FACS), expression of androgen receptor, p53 and cyclin dependent kinase inhibitors p27 and p21
by a combination of RT-PCR, real time-PCR, western blot and immuno-cytochemical analysis.
Results: Id4 expression was down-regulated in prostate cancer. Id4 expression was also down-
regulated in prostate cancer line DU145 due to promoter hyper-methylation. Ectopic Id4
expression in DU145 prostate cancer cell line led to increased apoptosis and decreased cell
proliferation due in part by an S-phase arrest. In addition to S-phase arrest, ectopic Id4 expression
in PC3 cells also resulted in prolonged G2/M phase. At the molecular level these changes were
associated with increased androgen receptor (AR), p21, p27 and p53 expression in DU145 cells.
Conclusion: The results suggest that Id4 acts directly as a tumor suppressor by influencing a
hierarchy of cellular processes at multiple levels that leads to a decreased cell proliferation and
change in morphology that is possibly mediated through induction of previously silenced tumor
suppressors.
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Background
The Id genes (Id1, Id2, Id3 and Id4) are part of the broader
basic helix loop helix family. The basic helix-loop-helix
(bHLH) proteins are DNA binding proteins that regulate
tissue-specific transcription within multiple cell lineages
[1]. Hetero- or homo-dimerization-dependent DNA bind-
ing activity of class A bHLH proteins are regulated to a
large part by the class D HLH inhibitors of differentiation
(Id) gene family [2]. The Id proteins lack the DNA binding
basic domain but have intact HLH domain [2,3]. This
domain configuration allows the Id family to dimerize
with bHLH transcription factors, but the lack of the basic
domain renders the Id-bHLH dimer transcriptionally
inactive, as it fails to bind and regulate promoter activity
of genes dependent on E-box (CANNTG) response ele-
ment [4]
The four different isoforms of Ids (Id1, Id2, Id3 and Id4)
have a highly conserved HLH domain but divergent N-
and C-terminal domains. This sequence divergence may
account for protein-specific interactions possibly resulting
in differential functions of Id proteins [5-7]. Although all
Id proteins interact with E-proteins, but isoform specific
bHLH and non-bHLH interactions are known to occur.
For example, interaction of a) Id2 directly with hypophos-
phorylated pRb protein family [8,9] and polycystins [10]
b) Id2 and Id4 with OLIG (class A bHLH, [11]) c) Id1 and
calcium/calmodulin-dependent serine protein kinase
(CASK) [12] and d) Id1 and Id3 with v-ets erythroblastosis
virus E26 oncogene homolog (Ets) [13] and Paired box
transcription factor (Pax) homeodomain containing pro-
teins [14]. Consistent with gene specific interactions, the
Id proteins also exhibit isoform specific functions such as
modulation of breast cancer 1, early onset (BRCA1) pro-
moter activity by Id4 [15,16], localization of Id1 to the
centrosomes [17] leading to accumulation of cells with
abnormal centrosome number and induction of apopto-
sis by Id2 in myeloid precursors, osteosarcoma [18] and
neuronal cells [19] by an HLH independent mechanism.
In general, Id proteins (Id1-3) promote cell proliferation
[20-22]. Consequently, the expression of Id proteins is
generally high in proliferating cells that is down-regulated
as a prerequisite for exit from the cell cycle during differ-
entiation [23]. Consistent with this observation, an
increased expression of various Id isoforms has been
detected in many cancers [24-32].
In comparison to Id1, Id2 and Id3, the function of Id4 is
less understood and often conflicting. Both tumor pro-
moting and tumor suppressor roles of Id4 have been
reported in many cancers. Tumor suppressor roles of Id4,
based on its loss of expression in association with pro-
moter hypermethylation have been suggested in leukemia
[33], breast [34,35], colorectal [36] and gastric cancers
[37]. The pro-tumor effect of Id4 is observed in bladder
[38] and rat mammary gland carcinomas [39]. Id4 is also
the only Id gene that is deregulated by a t(6;14)(p22;q32)
chromosomal translocation in a B-cell acute lymphoblas-
tic leukemia [40] and B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) [41].
The expression of Id4 in prostate epithelial cells is partic-
ularly interesting. Id4 appears to be androgen regulated in
normal prostate epithelial cells [42] and in the androgen
sensitive prostate cancer cell line LNCaP [43]. Id4 expres-
sion is undetectable or weakly expressed in androgen
independent DU145 cells whereas its expression is
observed (low) in PC3 prostate cancer cell lines [43].
LNCaP prostate cancer cells are generally considered less
tumorigenic and more differentiated as compared to
highly tumorigenic DU145 and PC3 prostate cancer cells.
These observations suggest that Id4 expression may be
associated with the state of differentiation and tumori-
genic potential of prostate epithelial cells. This hypothesis
was examined in the present study by over-expressing Id4
in androgen receptor negative DU145 and PC3 prostate
cancer cells. Our results, demonstrate that Id4 attenuates
cell cycle by promoting an S-phase arrest and induces
androgen receptor expression. Id4 expression is also sig-
nificantly reduced in prostate cancer samples as deter-
mined through data mining.
Methods
Cell Lines and Cell Culture
Human prostate cancer cell lines DU145 and LNCaP were
obtained from American Type Culture Collection (ATCC,
Rockville, MD). The DU145 cells were cultured in F12-
BCS-A (Ham's F12 (Gibco, Carlsbad, CA) medium con-
taining 10% Bovine Calf Serum (Hyclone) with appropri-
ate antibiotics (pen/strep, fungizone, and gentamycin).
LNCaP cells were cultured in RPMI-10% Fetal Calf Serum
(FCS) and antibiotics. The normal human prostate epithe-
lial cells (PrEC) were obtained from Cambrex (Baltimore,
MD) and were cultured in PrEGM (Cambrex, Baltimore,
MD) for approximately 10–15 doublings. Cells were cul-
tured at 37°C in a fully humidified atmosphere contain-
ing 5% CO2.
5'-Aza-2-Deoxycytidine (5-AZA-CdR) Treatment
The DU145 cells were cultured in F12-BCS-A containing 4
uM of 5-AZA-Cdr (4 uM). The media with freshly added
5-AZA-Cdr was changed every 24 hours for 96 hours
before harvesting the cells for RNA. The gene expression
was analyzed before and after 5-AZA-Cdr treatment on the
reverse transcribed RNA using gene specific primers.
Plasmids and transfections
The full length human Id4 cloned into pCMV vector
(pCMV-Id4) was a generous gift from Dr. Mark Israel. TheBMC Cancer 2009, 9:173 http://www.biomedcentral.com/1471-2407/9/173
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pCMV-Id4 vector and pCMV vector alone was transfected
in sub-confluent (60%) DU145 and PC3 cells grown in
six well plates using TransIT-prostate transfection reagent
cocktail (10 μl TransIT-prostate reagent, 5 μl prostate
boost reagent (Mirus Bio) and 2 μg pCMV-Id4 DNA in
200 ul of serum free media). The culture media was
changed once after an overnight incubation with the cock-
tail. Forty-eight hours after transfection, the cells with
incorporated pCMV-Id4 were selected by incubation in
fresh media containing 350 μg/ml G418 (Invitrogen) for
one week with media change every 2 days. Following this
selection cycle, the transfected cells were passaged once in
F12-BCS-A and then re-exposed to F12-BCS-A with 350 μg
of G418/ml for an additional week (second G418 selec-
tion). This approach ensured the survival of only trans-
fected cells. Simultaneous experiments were also
performed in which cells were transfected with no DNA
(control, parental) or with pCMV DNA (transfection con-
trol). The G418 selection procedure described above
resulted in no surviving DU145 parental cells. The cells
were grown to confluence (80%), trypsinized (0.25% v/v
trypsin and 0.03% w/v EDTA in calcium- and magnesium-
free phosphate buffered saline), counted, and plated at a
1:2 dilution in new 100-mm plates.
RNA preparation
Total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA) as described previously [43]. The final RNA
pellet was re-suspended in diethylpyrocarbonate (DEPC)-
treated H2O at a concentration of 1 mg/ml and stored at -
80°C until analysis.
Proliferation assay
DU145 cells were cultured at sub-confluent densities
(growth permissive, 40%) in 24 well plates (40% conflu-
ency) and serum starved for 48 hours. The cells were then
treated with 10% BCS for 20 h followed by a 6 h incuba-
tion with [3H] thymidine. Counts per min (cpm) of [3H]
thymidine incorporated into DNA were determined and
normalized to the total DNA per well. Total DNA content
was determined by SYBR green fluorescent assay [44].
Gene Expression
RNA (2 μg) was reverse transcribed in a final volume of 25
μl as per standard protocols (RT-Mix: 20 U RNAout (Inv-
itrogen, Carlsbad, CA); 1.25 mM each of dNTP's; 250 ng
oligo dT (Promega, Madison, WI), 10 mM dithiothreitol,
and 200 U MMLV reverse transcriptase (Invitrogen) in the
MMLV first-strand synthesis buffer (Invitrogen)). The
RNA was denatured for 10 min at 65°C, and then cooled
on ice before addition of RT mix and enzyme. The reverse
transcriptase reaction was carried out at 42°C for 1 h.
Each PCR reaction was performed with 250 pg reverse-
transcribed DNA using published protocols [43]. The pos-
sible contamination of RNA with DNA was distinguished
by performing the RT reaction without MMLV reverse
transcriptase enzyme (-MMLV RT). The PCR-based ampli-
fication reactions were carried out in duplicate on each
reverse-transcribed RNA sample using gene specific
primer sequences as indicated in respective figure legends.
Simultaneous PCR reactions were also carried out using
primers designed to β-actin to monitor the qualitative and
quantitative efficiency of the RT-PCR reactions. The iden-
tity of each of the corresponding PCR products was size
and sequence/restriction digest confirmed.
Real-Time PCR
Reverse transcribed RNA from DU145, DU145-Id4 and
DU145-pCMV cells were used for real time quantitative
gene expression analysis based on the TaqMan chemistry.
The validated probes for Id4, β-actin (control), E-cadherin
(CDH1), p21 (CDKN1A) and p53 were obtained from
Applied Biosystems. Amplification of target sequences
was detected with ABI7900HT sequence detection system
(Applied Biosystems, Foster City, CA) and analyzed with
ABI prism software (Applied Biosystems). All PCR reac-
tions were performed in a final volume of 50 μl according
to the manufacturer's instructions (Applied Biosystems).
The cycle threshold (Ct) was used to calculate relative
amounts of target RNA.
Immuno cytochemistry
The cells lines were cultured (60% confluency) in 8 cham-
ber slides (Lab-Tek) at 37°C as described above. After 2
days in culture, the media was removed and the adherent
cells were washed once with PBS. The cells were then fixed
in cold methanol (20C) for 1 hour and stored at -20C. The
fixed adherent cells on slides were equilibrated at 4C
before further processing. The slides were incubated in 3%
Bovine Serum Albumin (BSA) in PBS for 1 hour at 4C in
order to block non-specific sites. The slides were then
incubated with anti-Androgen Receptor-antibody
(1:10,000, PG21, Millipore) or anti-actin antibody
(1:10,000, H-196, Santa Cruz) for 1 hour at 4C. After pri-
mary antibody reaction, the cells were washed 3 times in
PBS for 5 minutes each and then incubated with Alexa
Fluor 594 anti-rabbit IgG (1:10, Invitrogen) at 4C for 1
hour. The slides were then rinsed for 5 × 5 minutes in PBS,
counter stained with DAPI (VWR), post fixed with 3.7%
formalin in PBS for 15 minutes and mounted with Glyc-
erol. Cells were examined using a Fluorescent Microscope
(Zeiss) and images captured via AxiomCam/AxioVision (v
4.4).
Western Blot Analysis
The prostate cancer cell lines were cultured on 150 mm
plates in their respective media. Cells (5 × 106) were dis-
sociated off the plate by adding ice cold PBS and scrap-BMC Cancer 2009, 9:173 http://www.biomedcentral.com/1471-2407/9/173
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ping with a cell scraper. Total cellular protein was
prepared as described previously [43].
20 ug of total protein was separated by 4–20% SDS-poly-
acrylamide gel (BioRad) and subsequently blotted onto a
nitrocellulose membrane (BioRad). The blotted nitrocel-
lulose membrane was subjected to western blot analysis
using protein specific antibodies (Id4: Aviva
ARP32335_T100) as mentioned above. After washing
with 1× PBS with 0.5% Tween 20, the membranes were
incubated with a secondary antibody against anti-rabbit
IgG (Pierce Rockford, IL) and the signal was visualized
using the Super Signal West Dura Extended Duration Sub-
strate (Pierce).
Flow Cytometric Analysis of Cell Cycle Progression and 
apoptosis
The DU145 and PC3 cells were cultured in 24 well plates
to a sub confluent density. After the culture the cells were
collected by trypsinization and washed with phosphate
buffered saline. The cells were then fixed with 70% etha-
nol and stored at -20°C overnight. The following day,
cells were washed twice with ice cold phosphate buffered
saline PBS/FCS (10%) followed by a final wash in 1× PBS.
The cells were then finally resuspended 1 ml of PBS (1×)
containing 50 μg/ml RNase A, 0.1% TritonX-100 and 1
mM EDTA and then incubated at 37°C for 30 minutes.
Finally, 20 μg/ml of propidium iodide was added. Data
acquisition and analysis were performed on a BD FACS-
can flow cytometer (Dept. of Biology, Spellman College,
Atlanta, GA). The cell cycle profiles were then analyzed
using BD Cellquest Pro (for apoptosis, Sub G0) and
MODFIT software cell cycle analysis. At least 10,000 cells
in each sample were analyzed to obtain a measurable sig-
nal. All measurements were performed using the same
instrument settings.
The fraction of cells in Sub G0 phase was used to detect
apoptotic cells. An increase in Sub G0 cells is due to loss
of fragmented DNA as a result of apoptosis from permea-
bilised cells (ethanol fixed) due to DNA fragmentation.
The cells stained with a DNA intercalating dye like propid-
ium iodide, results in a DNA profile representing cells in
G1, S-phase and G2M phase while the apoptotic cells are
represented by a sub G0/G1 population seen to the left of
the G0/G1 peak [45-47].
Statistical analysis
The ΔΔCt method (Applied Biosystems User Bulletin2;
ABI PRISM 7700 detection system) was used for relative
quantification of gene expression. The Ct values of the tar-
get genes from triplicate PCR reactions were normalized
to the levels of β-actin (endogenous control) from the
same cDNA preparations. The average Ct for each gene
was calculated by subtracting the Ct of the sample RNA
from that of the control RNA. This value or ΔCt reflected
the relative expression of the treated sample compared
with the control and became the exponent in the calcula-
tion for amplification 2ΔCtcont-ΔCtsample, the equivalent to
the fold change in expression. A statistically significant
difference between various treatments and/or cell lines
was determined by student's t-test.
DNA Methylation Analysis
The methylation status of the Id4 promoter region was
analyzed using methylation-specific PCR (MSP) [48]. This
assay entails the initial modification of genomic DNA by
sodium bisulfite, converting all un-methylated cytosines
to uracils, but leaving the methylated cytosines
unchanged. Subsequently, the DNA region of interest was
amplified in two separate reactions with primer pairs spe-
cific for either the methylated or the un-methylated
sequence.
Genomic DNA was isolated using DNeasy kit (Qiagen).
Approximately 1 μg of DNA was sodium bisulfite-modi-
fied and subjected to MSP as described previously [48].
MSP primers that specifically recognized un-methylated
Id4 sequence were 5'-GGT AGT TGG ATT TTT TGT TTT
TTA GTA TT-3' (sense) and 5'-AAC TAT ATT TAT AAA ACC
ATA CAC CCC A-3' (antisense); primers specific for the
methylated Id4 sequence were 5'-TAG TCG GAT TTT TCG
TTT TTT AGT ATC-3' (sense) and 5'-CTA TAT TTA TAA
AAC CGT ACG CCC CG-3' (antisense). The primers for
the U reaction cover the bases -194 until -166 and -60
until -33, and the primers for the M reaction cover the
bases -192 until -166 and -60 until -35 (relative to the
transcription start site). Reactions were hot-started at
95°C for 5 min and held at 80°C before addition of 0.625
U of Taq polymerase (Sigma, St. Louis, MO). Temperature
conditions for PCR were as follows: 35 cycles of 95°C for
30 sec, 58°C for 30 sec and 72°C for 30 sec, followed by
1 cycle of 72°C for 5 min. Normal DNA from peripheral
blood was treated in vitro with SssI methyltransferase
(New England Biolabs, Beverly, MA) in order to generate
a positive control for methylated alleles of Id4 [49]. PCR
products were separated on 2.5% agarose gels and visual-
ized by ethidium bromide staining.
Results
Id4 expression is down-regulated in prostate cancer
Data mining of published microarray databases was used
to determine the relative expression levels of Id4 in clini-
cally relevant cases of prostate cancer as compared to con-
trols and benign prostate hyperplasia. The consolidated
Oncomine database [50] was queried against Id4 and all
prostate databases were analyzed. Data from four of these
representative studies is shown in Fig. 1. Between these
four independent and unrelated studies [51-54], a total of
125 prostate cancer (PC), 13 metastatic prostate cancerBMC Cancer 2009, 9:173 http://www.biomedcentral.com/1471-2407/9/173
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(MPC), 53 normal controls (41 Normal (N), 2 normal
adjacent prostate (NAP), 7 normal adult prostate (NP), 3
post pubertal prostate (PP)), 28 benign prostate hyperpla-
sia (BP) and 13 prostate intra-epithelial neoplasia (PIN)
were analyzed. Normalized Id4 expression analysis in
these samples indicated: 1) High Id4 in benign prostate
hyperplasia as compared to prostate cancer suggesting
that decreased Id4 is a cancer specific event 2) High nor-
mal adjacent (NAP) and post pubertal (PP) Id4 gene
expression that may signify the role of Id4 in maintaining
normal prostate function and 3) Low Id4 expression in
prostate cancer (metastatic prostate cancer < prostate can-
cer). Consolidated data from all these studies demon-
strated that Id4 is significantly (T-values > 5 and low P-
values < E-6) down-regulated in prostate cancer samples.
The molecular basis of Id4 down-regulation and its signif-
icance in prostate cancer was studied in a well character-
ized prostate cancer cell line DU145. The DU145 prostate
cancer cell line is negative or expresses very low Id4 and
hence is an excellent model to study mechanisms
involved in its down-regulation. In contrast, the normal
human prostate epithelial cells (PrEC) and prostate cancer
cell lines (LNCaP) [43] express Id4.
Id4 expression in prostate cancer as determined from publically deposited microarray databases Figure 1
Id4 expression in prostate cancer as determined from publically deposited microarray databases. The Oncomine 
database was queried against Id4 and all prostate databases were analyzed. The box and whisker plots from four of these rep-
resentative studies is shown [51-54]. Consolidated data from all these studies demonstrated that Id4 is significantly (T-values > 
5 and low P-values < E-6) down-regulated in prostate cancer samples. Abbreviations: n: No. of samples in each analysis, PC: 
Prostate Cancer (Red), MPC: Metastatic prostate cancer (Yellow), NAP: Normal adjacent prostate (Blue), NP: Normal Pros-
tate (Blue), PP: Post-pubertal prostate (Blue), BP: Benign prostatic hyperplasia (Blue), PIN: prostate intra-epithelial neoplasia 
(green).
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Id4 promoter methylation in DU145 cells
Results shown in Fig. 2A demonstrate that DU145 cells
lack Id4 expression at the transcript and protein levels
[43]. Lack of Id4 in DU145 cells is possibly due to its pro-
moter hyper-methylation since treatment with global
demethylation agent 5'-Aza-2-Deoxycytidine (5-AZA-
CdR) resulted in the induction of Id4 gene and protein
expression (Fig. 2A). The methylation at the CpG island
located around the transcription start site leading to the
epigenetic silencing of Id4 in several human solid tumors
[33,34,36,37] have been reported. These results prompted
us to investigate the methylation status of the Id4 pro-
moter region in DU145 cells by MSP (Methylation Spe-
cific PCR). As shown in Fig. 2B, the Id4 promoter region
in DU145 cells is also methylated as compared to Id4
expressing LNCaP cells, human fibroblasts and normal
peripheral blood mononuclear cells. Thus, aberrant meth-
ylation of the promoter region appears to be associated
with Id4 gene silencing in AR negative DU145 cells.
Effect of Id4 on Cell Proliferation, Morphology and 
Apoptosis
Two weeks post-transfection, the expression of Id4 in
DU145 cells transfected with pCMV-Id4 was evaluated
with real time PCR analysis. A more than 10 fold increase
in Id4 expression in DU145-Id4 cell line as compared to
the parental DU145 cells confirmed that Id4 was being
expressed in the pCMV-Id4 transfected cells (after 1st
G418 selection). Similar levels of Id4 (range 7.5–11 fold)
was also observed after 2nd G418 selection. The Id4
expression in CMV transfected cells was negligible and
was comparable to that in parental DU145 cells. Follow-
ing this analysis, the cells were allowed to grow for at least
15 passages before subjecting to cellular/molecular analy-
sis.
A change in morphology in DU145-Id4 cell lines was
observed (Fig. 3). A significant observation was the
appearance of "epithelial like" morphology that was asso-
ciated with increased cell-cell adhesion of DU145-Id4
cells as compared to a mesenchymal morphology of the
parental DU145 cells (Fig. 3).
The slow but continuous rate of proliferation suggested
that DU145-Id4 cells have not undergone senescence (at
least until passage 28). In vitro growth curves (Doubling
time, Fig. 4A) indicated a decrease in cell proliferation
(increased doubling time) in DU145-Id4 cells as com-
(A) Id4 expression is generally absent in DU145 cells but present in androgen receptor positive LNCaP cells Figure 2
(A) Id4 expression is generally absent in DU145 cells but present in androgen receptor positive LNCaP cells. 
Treatment of DU145 cells with global de-methylation agent 5'-Aza-2-Deoxycytidine (5-AZA-CdR) leads to Id4 expression as 
determined by western blot analysis (upper panel) and reverse transcriptase polymerase chain reaction (RT-PCR, lower panel). 
Beta-actin was used as a loading and RT-PCR control. The primer pairs used for amplification were described in [43]. (B) Anal-
ysis of Id4 methylation in human fibroblasts (BJ) and the prostate cancer cell lines DU145, DU145-Id4 (DU145 cells with con-
stitutively expressed Id4) and LNCaP by methylation specific PCR (MSP). The presence of a PCR band in lanes marked "M" 
indicates a methylated gene sequence, the presence of a PCR band in lanes marked "U" indicates an un-methylated gene 
sequence. Normal peripheral blood cells (N), in vitro methylated DNA (IVD) and water served as controls.
U       M      U      M      U      M       U      M       U  M      U      M       U     M
BJ          DU145       LNCaP DU145+Id4        N             IVD           H2O
LNCaP
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pared to non-transfected DU145 and DU145-pCMV
(empty vector transfected) cells. The decreased prolifera-
t i o n  o f  D U 1 4 5 - I d 4  c e l l s  a s  c o m p a r e d  t o  D U 1 4 5  a n d
DU145-CMV were also reflected in 3H-thymidine incor-
poration assay that measures DNA synthesis (Fig. 4A).
Fluorescent Assisted Cell Sorting (FACS) was then used to
understand the effect of Id4 on cell cycle. Two different
approaches were used: The first approach was used to
determine the fraction of cells in the Sub-G0 population
as an estimate of apoptosis and the second approach,
using ModFit software was used to determine the fraction
of cells in each phase of the cell cycle. The DU145-Id4
cells demonstrated increased apoptosis as indicated by
increased cell counts in sub-G0 phase as compared to
DU145 cells (Fig. 4B).
The decreased proliferation of DU145-Id4 cells was due to
lower number of cells in the G0/G1 and G2/M phase (Fig.
5B) as compared to DU145 cells (Fig. 5A). A significant
observation was the increase in the number of cells in the
S-phase in DU145-Id4 cells (Fig. 5B) as compared to
DU145 cells (Fig. 5A). Collectively, these results demon-
strated that Id4 expression induces a change in cell mor-
phology/adhesion, decreased proliferation possibly to
due to an S-phase arrest and increased apoptosis.
The effect of Id4 expression on PC3 was also investigated
to confirm the results obtained from DU145 cells. PC3
cells are weakly positive for Id4 expression (Fig. 5C) but
nevertheless provide a good model to investigate the effect
of ectopic Id4 expression on prostate cancer cells (Fig.
5C). Although detailed analysis of PC3-Id4 cell line is
ongoing but initial results on cell cycle profiling by FACS
analysis demonstrated striking similarities to the DU145-
Id4 cells line. The PC3-Id4 cell line also demonstrated an
S-phase arrest (Fig. 5E) as compared to PC3 cells (Fig.
5D). The cell cycle profile between PC3 cells and PC3 cells
transfected with empty vector were similar (data not
shown). The ratio of cells in S-phase (% Cells in Id4 cell
lines/% cells in parental lines in each corresponding cell
cycle phase) in DU145-Id4 and PC3-Id4 were strikingly
similar (Fig. 5F). The data normalization also suggested
that unlike DU145-Id4, the PC3-Id4 cell line may have an
additional block at G2/M phase.
Gene Expression Changes in DU145-Id4 cell lines
The likely candidates involved in suppressing prolifera-
tion are the cyclin dependent kinase inhibitors (CDKNI)
p21 and p27. The expression of p21 and p27 in DU145-
Id4 cells was determined by semi-quantitative RT-PCR
analysis (Fig. 6A and 6B). The expression of p21 in
DU145-Id4 and normal prostate epithelial cells (PrEC)
was significantly higher as compared to parental DU145
cells (P < 0.05). The expression of p27 was also signifi-
cantly higher in DU145-Id4 cells as compared to DU145
cells in which it expression was absent or below detection
levels (P < 0.001). A highly significant increase (over 15
fold, Real Time PCR) in p53 transcript level was observed
in DU145-Id4 cell line as compared to DU145 cells (Fig.
6C). Thus, the decrease in DU145-Id4 cell proliferation
appears to be mediated in part by increased expression of
classical tumor suppressors' p27 and p21.
At the molecular level, the transition towards "epithelial
type" morphology and increased cell adhesion of DU145-
Id4 cells could be due an increase in E-cadherin expres-
sion as determined by real-time PCR analysis (Fig. 6C).
The E-cadherin expression in DU145-Id4 cells was at least
five fold higher than DU145 cells (Fig. 6C).
One of the hallmarks of the DU145 cell line, a represent-
ative of androgen depletion-independent cancers, is the
loss of androgen receptor. Based on our observations that
ectopic expression of Id4 can decrease proliferation,
increase apoptosis and induce a transition towards an epi-
thelial phenotype, we considered the possibility that Id4
Morphology (×100) of the DU145 and DU145-Id4 cell lines in culture Figure 3
Morphology (×100) of the DU145 and DU145-Id4 cell lines in culture. (A) Parental DU145 cells show a more mesen-
chymal morphology that is long and spindle shaped. (B & C) The DU145-Id4 cells appear more like epithelial cells that tend to 
adhere to each other hence appear as clusters. The DU145-Id4 cell line shown above is at passage 28.
A B CBMC Cancer 2009, 9:173 http://www.biomedcentral.com/1471-2407/9/173
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(A): Doubling time (in days, White bars) and rate of proliferation (Black bars) of DU145, DU145-CMV and DU145-Id4 cells  line in culture Figure 4
(A): Doubling time (in days, White bars) and rate of proliferation (Black bars) of DU145, DU145-CMV and 
DU145-Id4 cells line in culture. All the cell lines have matched passages. The DU145 cells were either transfected with no 
plasmid (DU145), CMV vector alone (DU145-CMV/EV) or pCMV-Id4 (DU145-Id4). White Bars: The average doubling time of 
DU145-Id4 cells as compared to DU145 and DU145-CMV. The data is an average cell count from four passages. The doubling 
time was calculated by counting days required for the number of plated cells (usually at 40% confluence) to reach confluence 
(80%). For DU145-Id4 cells, this average is from passage 13–16. A highly significant increase in the doubling time (approxi-
mately 2.5 fold) (P < 0.001) suggests that Id4 over-expression leads to a decrease in proliferation. Black Bars: 3H thymidine 
incorporation assay. 3H thymidine incorporation (CPM) was evaluated as a measure of rate of proliferation. The counts per 
minute (CPM) of incorporated 3H-thymidine was normalized to total DNA. The data represents CPM/ug DNA of cell lines at 
passages 14 and 15. The data is represented as mean ± SEM of three experiments performed in triplicates. *: P < 0.001. (B) 
FACS analysis of cell cycle parameters in DU145 and DU145-Id4 cell lines. The cell cycle profile showing fraction of cells in 
each phase of the cell cycle in DU145-Id4 and DU145 cells is shown. The data is representative of at least three experiments. 
The inset shows the fraction of cells in sub-G0 phase (normalized to 10,000 cells). The cells in sub-G0 phase have low DNA 
content possibly due to apoptosis. The mean ± SEM of three experiments performed in triplicate is shown (*: P < 0.001).
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FACS analysis of cell cycle parameters in DU145, DU145-Id4, PC3 and PC3-Id4 cell lines Figure 5
FACS analysis of cell cycle parameters in DU145, DU145-Id4, PC3 and PC3-Id4 cell lines. The cells were serum 
starved for 24 hours in order to synchronize the cell cycle. The cells were then serum stimulated (10% BCS) in order to deter-
mine the effect of Id4 on cell cycle. A and D: Serum treated DU145 and PC3 cells respectively, B and E: Serum treated 
DU145-Id4 and PC3-Id4 cells respectively. The cell cycle analysis and the fraction of cells in each phase (G0-G1, S and G2/M, 
indicated as % cells) were determined using ModFit cell cycle analysis software. The data is representative of triplicate experi-
ments. Of note is the number of cells (scale) represented on the Y-axis. C: Reverse Transcriptase polymerase chain reaction 
demonstrating the expression of Id4 in PC3 (lane 1) and PC3 cells stably transfected with Id4 expression plasmid (Lane 2). 
Weak Id4 expression was observed in PC3 cells whereas significantly higher expression was observed in PC3-Id4 cells (repre-
sentative of 3 different PCR reactions). F: The ratio of cells in each phase. The ratio was calculated by dividing the % cells in Id4 
expressing cells by parental cells in each phase of cell cycle. This calculation was used to normalize and compare the data 
between two cell lines. The error bars represent standard error of mean calculated from three different experiments (*: P > 
0.05 and ***: P > 0.001).
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may re-induce AR expression. Indeed, Id4 over expression
led to a highly significant increase in the expression of
androgen receptor in DU145 cells as determined by west-
ern blot analysis (Fig. 7A, upper panel), RT-PCR (Fig. 7A,
lower panel) and real time PCR (Fig. 7B). The androgen
receptor expression in DU145-Id4 cells was further con-
firmed at the cellular level by immuno-cytochemistry (Fig.
8A). As expected, the AR expression in DU145-Id4 cells
was localized primarily to the nucleus (Fig. 8A). A similar
AR expression was also observed in AR +ve LNCaP cells
(Fig 7A,B and Fig. 8E). Consistent with our RT-PCR and
western blot analysis, AR expression was largely absent in
parental DU145 cells (Fig 7A,B and Fig. 8C). Studies have
demonstrated that DU145 cells are negative for androgen
receptor due to promoter methylation [55] or express low
levels of androgen receptor [56]. Therefore, induction of
AR expression by Id4 can be due to a number of pathways,
most notably through demethylation of AR promoter
and/or induction of alternate transcriptional pathways
required for AR expression.
The Id family of bHLH proteins interacts with and nega-
tively regulates the bHLH proteins that generally induce
differentiation and block proliferation. Primary among
bHLH-Id interaction partners are the tumor suppressor
E2A proteins E12/E47 [57]. At the transcriptional level, Id
proteins also down regulate E2A [58,59]. Unexpectedly,
Id4 expression was associated with increased expression
of E12/E47 transcript (Fig. 7A). The induction of E12/E47
by Id4 therefore seems to be an isoform specific function
[58,59]. Thus, one of the mechanism by which Id4 may
exert its tumor suppressive effect is through up-regulation
of E12/E47 bHLH proteins that may in turn up-regulate
p21 [60] expression at transcriptional level.
(A): RT-PCR and semi-quantitative expression levels of cyclin dependent kinase inhibitors p27 and p21 in DU145, DU145-Id4  and PrEC (normal prostate epithelial) cells Figure 6
(A): RT-PCR and semi-quantitative expression levels of cyclin dependent kinase inhibitors p27 and p21 in 
DU145, DU145-Id4 and PrEC (normal prostate epithelial) cells. (B) Semi-quantitative analysis of RT-PCR results 
shown in (A). The intensity of each p27 and p21 band was normalized to constitutively expressed beta actin. The RT-PCR data 
and semi-quantitative analysis (expressed as mean ± SEM) is representative of 3 different RT and corresponding PCR reactions 
(***: P < 0.001, *: P < 0.05 as DU145). The following primers were used: p27 (CDKN1A): Forward 5'-TCA AAC GTG CGA 
GTG TCT AA and Reverse 5'-ACG TTT GAC GTC TTC TGA GG, p21: Forward 5'-CGA CTG TGA TGC GCT AAT G and 
Reverse 5'-TTA GGG CTT CCT CTT GGA GA, β-actin: Forward-5' AGA AAA TCT GGC ACC ACA CC, Reverse-5' GGG 
GTG TTG AAG GTC TCA AA. (C): Real time analysis of Id4, p53 and E-cadherin gene expression in DU145, DU145-CMV 
and DU145-Id4 cell lines. The data performed in triplicate is mean ± SEM from cells at passages 18, 20 and 23. The real time 
data is normalized to the constitutively expressed gene beta-actin. The relative expression levels were calculated by the Δ Ct 
method as described in materials and methods section. The RT-PCR data is representative of 3 different RT and corresponding 
PCR reactions (***: P < 0.001, as compared to DU145).
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Collectively, our results suggest that Id4 acts as a potential
tumor suppressor, possibly through multiple pathways.
The underlying molecular mechanisms are likely to be
complex that may involve gene specific Id4 targets or
more global, involving changes in response to trophic fac-
tors and modulation of overall transcriptional machinery.
Discussion
In this report we demonstrate that Id4 acts as a putative
tumor suppressor. The tumor suppressor role of Id4
appears to be unique as compared to other members of
the Id gene family (Id1, Id2 and Id3) that may act as onco-
genes or co-operating oncogenes in many cancers
[24,27,30].
Hypermethylation of CpG islands near gene promoter
regions is associated with transcriptional inactivation and
represents an important mechanism of gene silencing in
carcinogenesis [61,62]. Epigenetic silencing (promoter
hyper-methylation) of Id4 in cancers from different
organs such as in T-/natural killer acute lymphoblastic
leukemia [33], gastric [37], breast [35] and colorectal can-
cers [36] suggests its role as a putative tumor suppressor.
Analysis of public microarray databases provides strong
evidence that Id4 is down regulated in prostate cancer also
[51-54]. At the mechanistic level, the transcriptional inac-
tivation of Id4 is associated with aberrant promoter meth-
ylation in a model prostate cancer cell line DU145.
At the molecular level, its core function as a dominant
negative regulator of bHLH activity is conserved with its
other three family members (Id1, Id2 and Id3). Id4 effi-
ciently dimerizes with E proteins and blocks trans-activa-
tion of E box dependent genes [63]. Beyond this
conserved role, the non-bHLH interaction partners that
define global or cell type specific Id4 functions are largely
unknown. For example, interactions of Id2 with Rb [8,9]
and polycystins [10], Id1 and Id3 with Ets [13] transcrip-
tion factors largely contribute to their oncogenic potential
by releasing cell cycle blockade at multiple levels [32].
The effect of Id4 leading to decreased proliferation and S-
phase arrest in DU145 prostate cancer cell line may be due
to increase in the expression of tumor suppressors E-cad-
herin, p27, p21 and the bHLH transcription factors E12/
E47 [64-67] and/or activation of previously silenced
tumor suppressors. The increase in the transcript of p27
and p21 suggests that Id4 over-expression modifies intra-
(A): Western blot analysis of Androgen receptor expression analysis (Upper Panel) Figure 7
(A): Western blot analysis of Androgen receptor expression analysis (Upper Panel). Lower Panel: Expression of 
androgen receptor (AR) and E2A (E12/E47) bHLH transcription factor by RT-PCR. The gain of androgen receptor expression 
in DU145-Id4 cells as compared to DU145 cells at the transcript and protein level is evident. The total RNA and protein was 
purified from DU145-Id4 at passage 28 and analyzed for the expression studies. As controls, the parental, mock transfected 
DU145 cells (AR -ve) and LNCaP (AR +ve) cell lines were used. The expression of beta-actin was used as loading and RT-PCR 
control. The data is representative of at least three different RT-PCR reactions and Western blot analysis. The following prim-
ers were used: E2A F-5' CAC CAG CCC TCA TGC ACA ACC, R-5' CTC CAA CCA CAC CTG ACA C and androgen 
receptor (AR): F-5' ATG GTG AGC AGA GTG CCC TA and R-5' GTG GTG CTG GAA GCC TCT CCT. (B) Real time PCR 
analysis, performed on the same batch of reverse transcribed RNA used in panel A confirms the RT-PCR data. The fold change 
in AR expression is normalized to beta-actin (3 different RT reactions) and calculated by the Δ Ct method as described in 
materials and methods section (*** P < 0.001).
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cellular transcriptional pathways leading to increased p27
and p21 expression itself. The increase in E-cadherin
could be due to neutralization of bHLH transcriptional
inhibitors [68] by Id4 or a secondary event elicited by
increased p27 expression [69].
The p21 levels could be partially responsible for the
increased p53 expression [70] in DU145-Id4 cells. How-
ever, the S-phase arrest and apoptosis appears to be p53
dispensable since p53 is expressed in a mutant form (p53
mt/mt) in DU145 cells [71]. A similar S-phase arrest
observed in PC3-Id4 cells that are null for p53 further sup-
ports this mechanism. The p53 mutations in DU145 cells
are within the DNA binding domain (P223L and V274F)
that abrogates its transcriptional activity. The rate of apop-
tosis in DU145-Id4 expressing ectopic wild type p53 or
alternate apoptotic pathways involving NFkB, Bcl-2, Bcl-xl
needs to be investigated to further clarify mechanism of
action of Id4 in apoptosis and S-phase arrest. The epige-
netic silencing of p21 and p16 in PC3 cells as reported
previously [72,73] but not in DU145 (this study) suggest
that the molecular mechanisms involved in S-Phase and
G2/M phase arrest in PC3 cells could be unique that
remains to be investigated. Our data, however does con-
firm that Id4 is involved in blocking the cell cycle of pros-
tate cancer cell lines DU145 and PC3. It is also speculated
that the mechanism by which Id4 promotes S-phase arrest
could be independent of CDKNIs and involve mecha-
nisms that remains to be investigated.
Re-expression of functional AR can be achieved by treat-
ing the DU145 cells with non-selective de-methylating
agents such as 5-aza-2' deoxycytidine [55,74] or treatment
with growth factor NGF [75]. However, low AR expression
in spite of its promoter methylation reportedly exists in
DU145 cells [56]. An increased AR expression could there-
fore involve restoration of a transcriptional network by
Id4 in DU145 cells at the non-epigenetic (signaling, tran-
scriptional) level. A similar mechanism could also be
operational for p53 expression that involve Id4 directly,
or indirectly through increased p21 expression [70].
Evidence also suggests that Id4 can act as promoter of neo-
plastic transformation/growth. In breast cancer cells, Id4
and BRCA1 are in a negative feedback loop [15,16,76]. In
rat mammary gland carcinoma, Id4 expression is associ-
ated with proliferation and invasiveness [39]. In other
studies, Id4 was down regulated due to promoter hyper-
methylation in breast cancer [34,35]. Therefore, even in
cancers arising from the same organ such as the breast, Id4
may have opposing effects [15,16,34,35,39,76]. Id4 is
also over-expressed in acute lymphoblastic leukemia due
to a t(6;14)(p22;q32 translocation [40]. Thus, Id4 appears
to exhibit unique regulatory functions in diverse cancer
types. Collectively, these diverse and conflicting results
points towards a complex function of Id4 that is probably
dependent on a particular genetic background.
A recent report suggested a positive association between
Id4 expression and prostate cancer metastasis [77]. In this
report, the authors used an anti-Id4 antibody that cross-
reacts with multiple proteins in Western blot analysis in
our laboratory. On the contrary, our analysis of five inde-
pendent prostate cancer microarray databases strongly
Fluorescence immuno-cytochemistry demonstrating expres- sion and localization of androgen receptor (AR) at the cellu- lar level Figure 8
Fluorescence immuno-cytochemistry demonstrating 
expression and localization of androgen receptor 
(AR) at the cellular level. The cells were processed for 
immuno-cytochemistry as described in the materials and 
methods section. The red fluorescence demonstrates AR 
(panels A, C, E) or β-actin (panels B, D, F). The cells were 
counterstained with DAPI (blue) to reveal the nucleus. The 
red (antigen specific) and blue (nucleus) images were super-
imposed to demonstrate cellular localization of the antigen 
(AR or β-actin). Androgen receptor expression was localized 
primarily to the nucleus in LNCaP (panel E, AR+ve control) 
and DU145-Id4 (Panel A). In contrast, β-actin expression was 
primarily cytoplasmic (panels B, D, F). The AR expression in 
parental DU145 cells was not observed (panel C). Panels A 
and B: DU145-Id4, Panels C and D: DU145 and Panels E and 
F: LNCaP. The anti-AR and anti-β actin antibodies were 
highly specific and displayed no non-specific binding as deter-
mined by western blot analysis (e.g. Fig 7A). The photomi-
crographs (×200) are representative of at least 3 different 
experiments performed in replicates.
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suggests that Id4 is down-regulated in prostate cancer. The
development and use of a highly selective antibody will
thus ensure the quality and consistency of the data that
will significantly advance our understanding of Id4 pro-
tein expression in cancers.
Conclusion
The data strongly supports the role of Id4 as a putative
tumor suppressor that may act as a regulatory gene by
redirecting cell growth and differentiation. Nevertheless,
the opposing functions of Id4 in cancer cells suggest that
its molecular mechanism of action may depend on the
genotype that may be permissive for its pro- or anti-neo-
plastic function. This permissive genotype or a "switch"
will essentially be determined by the presence/absence of
specific Id4 interactions partners or signaling mechanisms
that modify response to trophic factors.
It is necessary to analyze Id4 methylation status and
expression levels in primary tumor samples as well as in
normal prostate tissues in order to further clarify the role
of epigenetic silencing of Id4 in prostate cancer. Since epi-
genetic aberrations are pharmacologically reversible, DNA
methylation changes have become attractive targets for
cancer treatment with de-methylating agents, leading to
reactivation of silenced genes. The identification of novel
target genes that may undergo epigenetic silencing in
prostate cancer will be important for the development of
future therapeutic and diagnostic strategies for clinical
application.
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